• USA Home
  • MTOX1016 - OATP1B3 Knockout HepaRG Cells

MTOX1016 Sigma-Aldrich

OATP1B3 Knockout HepaRG Cells

1 vial

  •  NACRES NA.81



Related Categories ADME/Tox Products, Cell Biology, Cell Line Models, Liver Drug Transporter/Toxicity Models
Quality Level   200
biological source   human female liver (hepatocarcinoma and hepatitis C tumor)
OMIM accession no.   605495
storage temp.   −196°C
Gene Information   human ... OATP1B3(28234)


General description

HepaRG is a human hepatoma cell line. The cells possess a pseudodiploid karyotype and have been characterized as an oval ductular bipotent hepatic cell line as they have the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO. HepaRG OATP1B3 knockout cells express the major xenobiotic sensors (PXR, CAR and AhR), drug transporters, phase I and II drug metabolizing enzymes as well as key hepatic transcription factors involved in stress response pathways.


See technical bulletin for detailed protocols

Features and Benefits

Zinc finger nucleases (ZFN) mediated Knock-out of SLCO1B3 (MRP3) gene.

• The frame-shift mutation of SLCO1B3 gene was confirmed by fragment length analysis and DNA sequencing.
• Loss of functionality was confirmed by loss of transport of selective substrates in sandwich culture assay.


Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation.

Legal Information

These products are covered by the License Agreement as described in Exhibit 1, 2 and 3, in the technical bulletin.

HepaRG is a trademark of BioPredic International company

Safety & Documentation

Safety Information

UN 3245 9
WGK Germany 
Flash Point(F) 
Not applicable
Flash Point(C) 
Not applicable


Certificate of Analysis (COA)

Please Enter a Lot Number
Protocols & Articles


The Role of Liver Transporters in Drug-Drug Interactions

Oral drug delivery involves dissolution in the small intestine and absorption across the enterocyte barrier into the portal vein followed by subsequent delivery through the liver into the systemic ci...
David C. Thompson, Ph.D, R&D Manager, Sigma® Life Science and Michael D. Mitchell, Product Manager, Sigma® Life Science
Biofiles Vol. 8, No. 12
Keywords: Absorption, Cancer, Clinical, Eliminations, Genetic, Metabolic Pathways, Metabolism, Pharmaceutical, Polymorphisms

Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?